You are here

N/A

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0109462
Agency Tracking Number: 0109462
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1104 Summit Ave., Suite 110
Plano, TX 75074
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Andres Romero
 (972) 578-8076
 aromero@microfab.com
Business Contact
 Donald Hayes
Title: President
Phone: (972) 578-8076
Email: dhayes@microfab.com
Research Institution
N/A
Abstract

This Small Business Innovation Research Phase I (SBIR) project will use ink-jet printing technology to fabricate precision biodegradable microspheres, 20-200m in diameter, for sustained-release of bioactive substances. The microspheres will be fabricated at specific diameters, as determined by the application, thereby producing an excellent platform for delivery of drugs, hormones, growth factor, DNA vectors / plasmids, cytokines, and enzymes. For the initial application, the microspheres will incorporate antineoplastic agents, such as taxol, for the treatment of head and neck cancer. The physical parameters of the microspheres will be verified with a scanning electron microscope. Release kinetics profiles of the taxol loaded microspheres will be determined by in vitro pharmacokinetic modeling. Quantification of antineoplastic agent release will be performed by High Performance Liquid Chromatography. Retention of efficacy will be tested by first fabricating the taxol microspheres and then extracting and testing the antineoplastic agent in a cell culture model of squamous cell carcinoma. The intact microspheres will also be tested in a nude mouse model of human squamous cell carcinoma.
The commercial applications of this project will be in human therapeutics as an alternative to conventional administration of those drugs that have a short half-life or that cause considerable systemic effects.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government